The molecular chaperone TRAP1 has been found upregulated in several cancer types, including breast, lung, prostate and colorectal cancers, where it is related to poor prognosis and advanced stages, whereas its genetic silencing induces an attenuation of cancer cells proliferation and in vivo tumor growth, providing a strong rationale for TRAP1 targeting as anticancer therapy (191). This evidence concerns the gene TRAP1 and neoplasm.